TY - JOUR
T1 - A Machine-Based Learning Model for Recurrence Prediction and Timing After Endoscopic Eradication Therapy for Barrett’s Esophagus
AU - Akshintala, Venkata
AU - Han, Samuel
AU - Yan, Yukun
AU - Bisschops, Raf
AU - Brennan, Case
AU - Cai, Yanna
AU - Codipilly, D. Chamil
AU - Cotton, Cary
AU - Early, Dayna
AU - Edmundowicz, Steven A.
AU - Eluri, Swathi
AU - Gallegos, Jazmyne
AU - Goyal, Rohit
AU - Hammad, Hazem T.
AU - Haidry, Rehan
AU - Hollander, Thomas
AU - Husain, Khalid
AU - Iyer, Prasad G.
AU - Jojo, Justeena
AU - Kushnir, Vladimir
AU - Komanduri, Srinadh
AU - Leggett, Cadman
AU - Lovat, Laurence
AU - Muthusamy, V. Raman
AU - Rastogi, Amit
AU - Seewald, Stefan
AU - Shaheen, Nicholas J.
AU - Thaker, Adarsh
AU - Vantanasiri, Kornpong
AU - Jones, Craig
AU - Wani, Sachin
N1 - Publisher Copyright:
© 2026 American Gastroenterological Association Institute.
PY - 2026
Y1 - 2026
N2 - Background & Aims Tools that can predict recurrence in patients with Barrett’s esophagus (BE)-related neoplasia treated with endoscopic eradication therapies (EET) to guide surveillance decisions are needed. We aimed to develop and validate a machine learning (ML)-based prediction tool to predict the risk and timing of recurrence status post EET. Methods Three prospective United States databases of patients who underwent EET for BE-related neoplasia and achieved complete eradication of intestinal metaplasia (CE-IM; n = 1114) were utilized to develop and internally validate a ML-based prediction tool using the Random Forest model and imputation techniques. Predictors incorporated in this model included demographics, endoscopy and pathology results, and EET details. A Cox proportional hazards model was utilized to predict the time to recurrence. External validation was performed using the United States Radiofrequency Ablation database (n = 1397). Results BE recurrence occurred in 29.2% (n = 734) of patients and BE-related neoplasia recurrence in 10.6% (n = 265), with a mean time to recurrence of 21.3 months (mean follow-up, 37.7 months). The top predictors for recurrence included BE length, body mass index, age, sessions needed to achieve CE-IM, and baseline histology. The model was well-calibrated, and area under the receiver operating characteristic curve (AUC) was 0.92 (95% confidence interval [CI], 0.85–0.95) on internal validation and 0.91 (95% CI, 0.87–0.95) on external validation for BE recurrence. For BE-related neoplasia recurrence, the AUC was 0.90 (95% CI, 0.88–0.93). The model had moderate discriminative performance to predict timing of recurrence with a C-index of 0.701 at 1 year (AUC 0.71), 0.68 (AUC 0.69) at 3 years, and 0.66 (AUC 0.69) at 5 years. Conclusions This United States-based externally validated tool accurately predicts BE and BE-related neoplasia recurrence and timing post EET. This practical tool may help provide a personalized approach to surveillance strategies.
AB - Background & Aims Tools that can predict recurrence in patients with Barrett’s esophagus (BE)-related neoplasia treated with endoscopic eradication therapies (EET) to guide surveillance decisions are needed. We aimed to develop and validate a machine learning (ML)-based prediction tool to predict the risk and timing of recurrence status post EET. Methods Three prospective United States databases of patients who underwent EET for BE-related neoplasia and achieved complete eradication of intestinal metaplasia (CE-IM; n = 1114) were utilized to develop and internally validate a ML-based prediction tool using the Random Forest model and imputation techniques. Predictors incorporated in this model included demographics, endoscopy and pathology results, and EET details. A Cox proportional hazards model was utilized to predict the time to recurrence. External validation was performed using the United States Radiofrequency Ablation database (n = 1397). Results BE recurrence occurred in 29.2% (n = 734) of patients and BE-related neoplasia recurrence in 10.6% (n = 265), with a mean time to recurrence of 21.3 months (mean follow-up, 37.7 months). The top predictors for recurrence included BE length, body mass index, age, sessions needed to achieve CE-IM, and baseline histology. The model was well-calibrated, and area under the receiver operating characteristic curve (AUC) was 0.92 (95% confidence interval [CI], 0.85–0.95) on internal validation and 0.91 (95% CI, 0.87–0.95) on external validation for BE recurrence. For BE-related neoplasia recurrence, the AUC was 0.90 (95% CI, 0.88–0.93). The model had moderate discriminative performance to predict timing of recurrence with a C-index of 0.701 at 1 year (AUC 0.71), 0.68 (AUC 0.69) at 3 years, and 0.66 (AUC 0.69) at 5 years. Conclusions This United States-based externally validated tool accurately predicts BE and BE-related neoplasia recurrence and timing post EET. This practical tool may help provide a personalized approach to surveillance strategies.
KW - Barrett’s Esophagus
KW - Endoscopic Eradication Therapy
KW - Recurrence
KW - Surveillance
UR - https://www.scopus.com/pages/publications/105042266682
U2 - 10.1016/j.cgh.2026.03.026
DO - 10.1016/j.cgh.2026.03.026
M3 - Article
C2 - 41956235
AN - SCOPUS:105042266682
SN - 1542-3565
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
ER -